Correlation of activity of chlorpromazine and respective hydroxy, dimethoxy and sulphoxide analogues on dopamine, muscarinic, histamine and calmodulin sites of action

References

• Alfredssen G., Lindberg M., Sedvall G. The presence of 7-hydroxychlorpromazine in CSF of chlorpromazine-treated patients. Psychopharmacology 1982; 77: 376–378
   PubMedGoogle Scholar
• Creese I., Manian A. A., Prosser T. D., Snyder S. H. 3H-Haloperidol binding to dopamine receptors in rat corpus striatum: Influence of the chloromazine metabolites and derivatives. European Journal of Pharmacology 1978; 47: 291–296
   PubMedGoogle Scholar
• Curry S. H., Evans S. Assay of 7-hydroxychlorpromazine and failure to detect more than small quantities, in plasma of responding schizophrenics. Psychopharmacology Communications 1975; 1: 481–490
   PubMedGoogle Scholar
• DeLean A. P., Munson P. J., Rodbard D. Simultaneous analysis of families of sigmoidal curves: Application to bioassay, radioligand assay, and physiological dose-response curves. American Journal of Physiology 1978; 235: E97–E102
   PubMed Web of Science ®Google Scholar
• Enjalbert A., Hamon J., Bourgoin S., Bockaert J. Postsynaptic serotonin-sensitive adenylate cyclase in the central nervous system. Molecular Pharmacology 1978; 14: 11–23
   PubMedGoogle Scholar
• Ferguson G. A. Statistical Analysis in Psychology and Education2nd ed. McGraw Hill, New York 1966; 216–220
   Google Scholar
• Green J. P. Histamine receptors in brain. Handbook of Psychopharmacology, L. Iversen, S. D. Iversen, S. H. Snyder. Plenum, New York 1983; Vol. 17: 385–420
   Google Scholar
• Grigoriadis D., Seeman P. The dopamine-neuroleptic receptor. Canadian Journal of Neurological Sciences 1984; 11: 108–113
   PubMedGoogle Scholar
• Hals P. A, Hall H., Dahl S. G. Phenothiazine drug metabolites: Dopamine D2 receptor, α1-and α2-adrenoceptor binding. European Journal of Pharmacology 1986; 125: 373–381
   PubMedGoogle Scholar
• Hamblin M. W., Leff S. E., Creese I. Interactions of agonists with D-2 receptors: Evidence for a single receptor population existing in multiple agonist affinity-states in rat striatal membranes. Biochemical Pharmacology 1984; 33: 877–887
   PubMed Web of Science ®Google Scholar
• Hoss W., Ellis J. Muscarinic receptor subtypes in the central nervous system. International Review of Neurobiology 1985; 26: 151–199
   PubMedGoogle Scholar
• Kaul P. N., Pabrai P. R., Farmer M. Chlorpromazine metabolism VI—Adrenolytic and antiserotonergic activities of chlorpromazine and its various metabolites. Archives Internationals Pharmacodynamic Therapie 1973; 206: 325–337
   PubMedGoogle Scholar
• Krieglstein J., Rieger H., Schultz H. Comparative study on the activity of chlorpromazine and 7-hydroxychlorpromazine in the isolated perfused rat brain. Biochemical Pharmacology 1980; 29: 63–67
   PubMedGoogle Scholar
• Lal S., Sourkes T. L. Effect of various chlorpromazine metabolites on amphetamine-induced stereotyped behavior in the rat. European Journal of Pharmacology 1972; 17: 283–286
   PubMedGoogle Scholar
• Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Luthin G. R., Wolfe B. B. Comparison of 3‘H’pirenzepine and 3‘H’quincuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain. Journal of Pharmacology and Experimental Therapeutics 1984; 228: 648–665
   PubMedGoogle Scholar
• Mackay H. V. P., Healey H. F., Baker J. The relationship of plasma chlorpromazine to its 7-hydroxy and sulphoxy metabolites in a large population of chronic schizophrenics. British Journal of Clinical Pharmacology 1974; 1: 425–430
   PubMed Web of Science ®Google Scholar
• Meltzer H. Y., Fang V. S., Simonovich M., Paul S. M. Effect of metabolites of chlorpromazine on plasma prolactin levels in male rats. European Journal of Pharmacology 1977; 41: 431–436
   PubMed Web of Science ®Google Scholar
• Miller R. J., Hiley C. R. Anti-muscarinic properties of neuroleptics and drug-induced parkinsonism. Nature 1974; 248: 596–597
   PubMed Web of Science ®Google Scholar
• Miller R. J., Iversen L. L. Effect of chlorpromazine and some of its metabolites on the dopamine-sensitive adenylate cyclase of rat brain striatum. Journal of Pharmacy and Pharmacology 1974; 26: 142–144
   PubMedGoogle Scholar
• Norman J. A., Drummond A. H., Moser P. Inhibition of calmodulin-dependent regulator-stimulated phosphodiesterase activity by neuroleptic drugs is unrelated to their clinical efficacy. Molecular Pharmacology 1979; 16: 1089–1094
   PubMed Web of Science ®Google Scholar
• Palmer G. C., Manian A. A. Actions of neuroleptic agents on central cyclic nucleotide systems. Neuropharmacology of Cyclic Nucleotides, G. C. Palmer. Urban & Schwarzenberg, Baltimore/Munich 1979; 53–111
   Google Scholar
• Palmer G. C. Effects of psychoactive drugs on cyclic nucleotides in the central nervous system. Progress in Neurobiology 1983; 21: 1–133
   PubMedGoogle Scholar
• Palmer G. C., Pajer K. A., Manian A. A. Comparison of inhibitory actions of chlorpromazine or its 7,8-dihydroxy-and 7,8-dioxo-didesmethyl analogs on DA-sensitive adenylate cyclase and calmodulin activation of phosphodiesterase in rat striatum. Archives Internationals Pharmacodynamic Therapie 1985; 273: 202–211
   PubMedGoogle Scholar
• Perel J. M., Manian A. A. Pharmacokinetics of Therapeutic Toxic Reactions: I. Phenothiazines Neurotoxicology, L. Roizin, H. Shiraki, N. Grcevic. Raven Press, New York 1977; 9–13
   Google Scholar
• Prozialeck W. C., Weiss B. Inhibition of calmodulin by phenothiazines and related drugs: Structure activity relationships. Journal of Pharmacology and Experimental Therapeutics 1982; 222: 509–516
   PubMed Web of Science ®Google Scholar
• Richelson E. Antipsychotics block muscarinic acetylcholine receptor-mediated cyclic GMP formation in cultured mouse neuroblastoma cells. Nature 1977; 266: 371–373
   PubMedGoogle Scholar
• Richelson E., Nelson A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. European Journal of Pharmacology 1984; 103: 197–204
   PubMed Web of Science ®Google Scholar
• Sakalis G., Chan T. L., Gershon S., Park S. The possible role of metabolites in therapeutic response to chlorpromazine treatment. Psychopharmacologia 1973; 32: 279–284
   PubMedGoogle Scholar
• Seeman P. Dopamine/neuroleptic receptors in schizophrenia. Handbook of Studies of Schizophrenia 1986; 2: 243–251
   Google Scholar
• Snyder S., Greenberg D., Yamamura H. I. Antischizophrenic drugs and brain cholinergic receptors. Archives of General Psychiatry 1974; 31: 58–61
   PubMed Web of Science ®Google Scholar
• Sokoloff P., Martres M. P., Protais P., Costentin J., Schwartz J. C. Two distinct classes of dopamine receptors mediating the action of antipsychotics: Binding and behavioral studies. Molecular Pharmacology of Neurotransmitter Receptors, T. Segawa. Raven Press, New York 1983; 163–173
   Google Scholar
• Thompson W. J., Terasaki W. L., Epstein P. M., Strada S. J. Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Advances in Cyclic Nucleotide Research 1979; 10: 69–92
   PubMedGoogle Scholar
• Turano P., Turner W. J., Manian A. A. Thin-layer chromatography of chloropromazine metabolites. Attempt to identify each of the metabolites appearing in blood, urine and faeces of chronically medicated schizophrenics. Journal of Chromatography 1973; 75: 277–293
   PubMed Web of Science ®Google Scholar
• Yamamura H. I., Manian A. A., Snyder S. H. Muscarinic cholinergic receptor binding: Influence of pimozide and chlorpromazine metabolites. Life Sciences 1976; 18: 685–692
   PubMedGoogle Scholar